MW 607.6 Da, Purity >98%. Potent, selective, ATP-competitive mTOR inhibitor that directly inhibits both mTORC1 and mTORC2 complexes, with IC50 values between 2 and 10 nM in in vitro kinase assays. Displays 1000-fold selectivity for mTOR over PI3K, 200-fold selectivity for mTOR over DNA-PK, ATM and hVps34, and exhibits 100-fold binding selectivity relative to 450 other protein kinases. Impairs cell growth and proliferation.
1-phosphatidylinositol 3-kinase, 5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha, 5-bisphosphate 3-kinase 110 kDa catalytic subunit delta, 5-bisphosphate 3-kinase 110 kDa catalytic subunit gamma, 5-bisphosphate 3-kinase catalytic subunit alpha isoform, 5-bisphosphate 3-kinase catalytic subunit delta isoform, 5-bisphosphate 3-kinase catalytic subunit gamma isoform, A930014J19Rik, APDS, C2 containing phosphatidylinositol kinase, C2 domain containing alpha polypeptide, CDC42 binding protein kinase alpha (DMPK like), CDC42 binding protein kinase alpha dmpk like, CDC42 binding protein kinase beta, CDC42-binding protein kinase alpha, CDC42BPA, CLOVE, CPK, CWS5, Class 2 alpha polypeptide, Cpk m, DKFZp686L1738, DKFZp686L193, DKFZp686O1820, DKFZp686P1738, DMPK like, DMPK-like alpha, DNA PK, DNA-PK catalytic subunit, DNA-PKcs, DNA-dependent protein kinase catalytic subunit, DNPK 1, FK506 binding protein 12 rapamycin associated protein 1, FK506 binding protein 12 rapamycin associated protein 2, FK506-binding protein 12-rapamycin complex-associated protein 1, FKBP rapamycin associated protein, FKBP12-rapamycin complex-associated protein, FKBP12-rapamycin complex-associated protein 1, FLJ23347, FLJ30129, FLJ44809, FRAP, FRAP1, FRAP2, GRB 1, HYRC, HYRC 1, Hyper radiosensitivity of murine scid mutation, complementing 1, Hyperradiosensitivity complementing 1, mouse, homolog of 1, IMD14, IMD26, KIAA0451, MCAP, MCM, MCMTC, MGC142161, MGC142163, MGC142218, MGC189823, MGC61518, MRCK alpha, MRCKA_HUMAN, MTOR_HUMAN, Mammalian target of rapamycin, Mechanistic target of rapamycin, Myotonic dystrophy kinase related CDC42 binding protein kinase alpha, Myotonic dystrophy kinase-related CDC42-binding kinase alpha, Myotonic dystrophy protein kinase-like alpha, NPIK, OTTHUMP00000001983, OTTHUMP00000035727, OTTHUMP00000035728, OTTHUMP00000035729, OTTHUMP00000035730, OTTHUMP00000231763, P3C2A_HUMAN, P85A_HUMAN, PI 3 Kinase catalytic subunit alpha, PI 3 Kinase catalytic subunit gamma, PI3 kinase p110 subunit alpha, PI3 kinase p110 subunit delta, PI3 kinase p110 subunit gamma, PI3 kinase p85, PI3 kinase p85 subunit alpha, PI3-K-C2(ALPHA), PI3-K-C2A, PI3-kinase regulatory subunit alpha, PI3-kinase subunit alpha, PI3-kinase subunit delta, PI3-kinase subunit gamma, PI3-kinase subunit p85-alpha, PI3-kinase type 3, PI3CG, PI3K, PI3K p85, PI3K regulatory subunit alpha, PI3K type 3, PI3K-C2-alpha, PI3K-alpha, PI3K-delta, PI3K-gamma, PI3KC A, PI4K-beta, PI4K92, PI4KB_HUMAN, PI4KIIIbeta, PIK3, PIK3C 2A, PIK3C A, PIK3R1, PIK4CB, PK3C3_HUMAN, PK3CA_HUMAN, PK3CD_HUMAN, PK3CG_HUMAN, PKRDC, PRKDC_HUMAN, Phosphatidylinositol 3 kinase catalytic alpha polypeptide, Phosphatidylinositol 3 kinase associated p 85 alpha, Phosphatidylinositol 3 kinase catalytic 110 KD alpha, Phosphatidylinositol 3 kinase catalytic 110 kD gamma, Phosphatidylinositol 3 kinase catalytic delta polypeptide, Phosphatidylinositol 3 kinase class 2 alpha, Phosphatidylinositol 3 kinase class 3, Phosphatidylinositol 3 kinase gamma, p110 gamma, Phosphatidylinositol 3 kinase regulatory 1, Phosphatidylinositol 3 kinase, catalytic, gamma polypeptide, Phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 1 (p85 alpha), Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha, Phosphatidylinositol 3-kinase catalytic subunit type 3, Phosphatidylinositol 3-kinase p100 subunit, Phosphatidylinositol 3-kinase regulatory subunit alpha, Phosphatidylinositol 4 5 bisphosphate 3 kinase 110 kDa catalytic subunit gamma, Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha, Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform, Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit delta isoform, Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit gamma, Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit gamma isoform, Phosphatidylinositol 4 kinase catalytic beta, Phosphatidylinositol 4 kinase catalytic beta polypeptide, Phosphatidylinositol 4 kinase wortmannin sensitive, Phosphatidylinositol 4,5 bisphosphate 3 kinase 110 kDa catalytic subunit alpha, Phosphatidylinositol 4,5 bisphosphate 3 kinase 110 kDa catalytic subunit delta, Phosphatidylinositol 4,5 bisphosphate 3 kinase, catalytic subunit delta, Phosphatidylinositol 4-kinase beta, Phosphatidylinositol-4, Phosphatidylinositol-4-phosphate 3-kinase C2 domain-containing subunit alpha, Phosphoinositide 3 kinase B, Phosphoinositide 3 kinase C, Phosphoinositide 3 kinase catalytic alpha polypeptide, Phosphoinositide 3 kinase catalytic delta polypeptide, Phosphoinositide 3 kinase class 2 alpha, Phosphoinositide 3 kinase gamma catalytic subunit, Phosphoinositide 3 kinase, catalytic, delta polypeptide variant p37delta, Phosphoinositide 3 kinase, class 2, alpha polypeptide, Phosphoinositide 3 kinase, regulatory subunit 1 (alpha), Phosphoinositide 3-Kinase-C2-alpha, Phosphoinositide-3-kinase catalytic gamma polypeptide, Phosphoinositide-3-kinase class 3, Pik3c3, Pik3cd, Pik3cg, Protein Kinase DNA Activated Catalytic Polypeptide, PtdIns 3 kinase p110, PtdIns 3 kinase p85 alpha, PtdIns 4 kinase, PtdIns 4-kinase beta, PtdIns-3-kinase C2 subunit alpha, PtdIns-3-kinase regulatory subunit alpha, PtdIns-3-kinase regulatory subunit p85-alpha, PtdIns-3-kinase subunit alpha, PtdIns-3-kinase subunit delta, PtdIns-3-kinase subunit gamma, PtdIns-3-kinase subunit p110-alpha, PtdIns-3-kinase subunit p110-delta, PtdIns-3-kinase subunit p110-gamma, PtdIns-3-kinase type 3, RAFT1, RAPT1, RP5-1087E8.4, Rapamycin and FKBP12 target 1, Rapamycin associated protein FRAP2, Rapamycin target protein, Rapamycin target protein 1, Ser thr protein kinase PK428, Ser thr protein kinase related to the myotonic dystrophy protein kinase, Serine/threonine protein kinase PIK3CA, Serine/threonine protein kinase PIK3CG, Serine/threonine-protein kinase MRCK alpha, Serine/threonine-protein kinase mTOR, Type III phosphatidylinositol 4 kinase beta, XRCC 7, caPI3K, dJ576K7.1 (FK506 binding protein 12 rapamycin associated protein 1), hVps34, mrck, p110 alpha, p110 gamma, p110D, p110delta, p110dp85a, p120-PI3K, p350, p460, p85, p85-ALPHA, pk428
MW 607.6 Da, Purity >98%. Potent, selective, ATP-competitive mTOR inhibitor that directly inhibits both mTORC1 and mTORC2 complexes, with IC50 values between 2 and 10 nM in in vitro kinase assays. Displays 1000-fold selectivity for mTOR over PI3K, 200-fold selectivity for mTOR over DNA-PK, ATM and hVps34, and exhibits 100-fold binding selectivity relative to 450 other protein kinases. Impairs cell growth and proliferation.
Soluble in DMSO to 3 mM.
Potent, selective, ATP-competitive mTOR inhibitor that directly inhibits both mTORC1 and mTORC2 complexes, with IC50 values between 2 and 10 nM in in vitro kinase assays. Displays 1000-fold selectivity for mTOR over PI3K, 200-fold selectivity for mTOR over DNA-PK, ATM and hVps34, and exhibits 100-fold binding selectivity relative to 450 other protein kinases. Impairs cell growth and proliferation.
This product is manufactured by BioVision, an Abcam company and was previously called 2273 Torin 1. 2273-25 is the same size as the 25 mg size of ab218606.
DNA-PKcs also known as DNA-dependent protein kinase catalytic subunit is a large serine/threonine protein kinase with a mass of approximately 469 kDa. It is mainly expressed in the nucleus of cells and is involved in DNA damage repair processes. Another key molecule mTOR (mechanistic target of rapamycin) a 289 kDa protein integrates signals for nutrient and energy status to control cell growth. PI 3 Kinase family members including PI 3 Kinase p110 delta PI 3 Kinase p85 alpha VPS34 (Class III PI3K) PI 3 Kinase catalytic subunit alpha/PIK3CA PI 3 Kinase Class 2A/Cpk and PI 3 Kinase catalytic subunit gamma/PI3K-gamma contribute to various cellular functions through lipid signaling within the cytoplasm and plasma membrane. PI4 kinase beta (PI4KB) facilitates phosphatidylinositol 4-phosphate production relevant in multiple cell processes.
DNA-PKcs plays a vital role in the non-homologous end joining (NHEJ) repair pathway essential for fixing DNA double-strand breaks. mTOR is a central regulator of cell metabolism growth proliferation and survival. PI 3 Kinase proteins through phosphorylation of inositol lipids on the cell membrane involve themselves in signal transduction pathways that regulate cell growth proliferation survival and differentiation. Some PI 3 Kinases such as p110 delta and VPS34 function within specific complexes like the phosphatidylinositol 3-kinase complex I. CDC42 binding protein kinase alpha (also known as MRCK alpha) influences cytoskeletal dynamics and cell motility by interacting with small GTPase CDC42.
These targets participate in key pathways such as the PI3K-AKT-mTOR signaling pathway and the DNA damage response (DDR) pathway. The PI3K-AKT-mTOR pathway featuring proteins like mTOR and PI 3 Kinase catalytic subunits is important for regulating cell growth and metabolism. In the DDR pathway DNA-PKcs and related proteins like ATM (ataxia-telangiectasia mutated) and ATR (ATM and Rad3-related) help in recognizing and repairing DNA damages. These pathways ensure cellular responses to external and internal stimuli maintaining cellular homeostasis and genomic integrity.
Dysregulation in these proteins links to conditions like cancer and diabetes. For instance mutations in PI 3 Kinase catalytic subunit alpha (PIK3CA) frequently occur in various cancers affecting cell proliferation and survival. Abnormal mTOR signaling is associated with metabolic disorders including type 2 diabetes due to its role in insulin signaling pathways. Furthermore DNA repair defects involving DNA-PKcs could contribute to the development of cancer particularly in combination with mutations in other DDR-related proteins such as BRCA1/2. These relations in pathways highlight the importance of these proteins in disease progression and therapeutic targeting.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com